Bristol Myers Squibb (BMY) EBITDA Margin (2009 - 2026)
Bristol Myers Squibb (BMY) reported EBITDA Margin of 24.65% for Q1 2026, up 437.0% year-over-year from 4.59% in Q1 2025, and up 186.67% on a QoQ basis from 8.6% in Q4 2025.
Bristol Myers Squibb (BMY) has 18 years of EBITDA Margin data on file, last reported at 24.65% in Q1 2026.
- Quarterly EBITDA Margin rose 437.0% year-over-year to 24.65% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.12% (up 379.0% YoY) and the FY2025 annual result came in at 14.04%, up 3193.0% from the prior year.
- EBITDA Margin advanced to 24.65% in Q1 2026 per BMY's latest filing, from 8.6% in the prior quarter.
- Across five years, EBITDA Margin topped out at 24.65% in Q1 2026 and bottomed at 99.16% in Q1 2024.
- The 5-year median for EBITDA Margin is 13.87% (2022), against an average of 7.77%.
- The widest annual swing landed in 2024, when EBITDA Margin plunged 11834 bps; it then surged 11943 bps in 2025.
- Tracing BMY's EBITDA Margin over 5 years: stood at 13.87% in 2022, then dropped by 6 bps to 13.09% in 2023, then tumbled by 81 bps to 2.45% in 2024, then soared by 251 bps to 8.6% in 2025, then surged by 187 bps to 24.65% in 2026.
- Per Business Quant, the three latest BMY EBITDA Margin figures stand at 24.65% (Q1 2026), 8.6% (Q4 2025), and 18.34% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 24.65% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.65% |
| Dec 31, 2025 | 8.60% |
| Sep 30, 2025 | 18.34% |
| Jun 30, 2025 | 9.63% |
| Mar 31, 2025 | 20.27% |
| Dec 31, 2024 | 2.45% |
| Sep 30, 2024 | 10.08% |
| Jun 30, 2024 | 13.31% |
| Mar 31, 2024 | -99.16% |
| Dec 31, 2023 | 13.09% |
| Sep 30, 2023 | 18.50% |
| Jun 30, 2023 | 18.30% |
| Mar 31, 2023 | 19.18% |
| Dec 31, 2022 | 13.87% |
| Sep 30, 2022 | 15.66% |
| Jun 30, 2022 | 13.95% |
| Mar 31, 2022 | 11.31% |
| Dec 31, 2021 | 21.09% |
| Sep 30, 2021 | 14.11% |
| Jun 30, 2021 | 9.24% |
| Mar 31, 2021 | 20.92% |
| Dec 31, 2020 | -120.72% |
| Sep 30, 2020 | -2.32% |
| Jun 30, 2020 | -10.58% |
| Mar 31, 2020 | -36.79% |
| Dec 31, 2019 | -32.99% |
| Sep 30, 2019 | -7.34% |
| Jun 30, 2019 | -3.12% |
| Mar 31, 2019 | 2.62% |
| Dec 31, 2018 | -1.76% |
| Sep 30, 2018 | 9.12% |
| Jun 30, 2018 | -19.42% |
| Mar 31, 2018 | 3.76% |
| Dec 31, 2017 | -16.57% |
| Sep 30, 2017 | -7.54% |
| Jun 30, 2017 | -5.33% |
| Mar 31, 2017 | 14.00% |
| Dec 31, 2016 | -6.10% |
| Sep 30, 2016 | 5.16% |
| Jun 30, 2016 | 8.40% |
| Mar 31, 2016 | 13.73% |
| Dec 31, 2015 | -31.77% |
| Sep 30, 2015 | -2.70% |
| Jun 30, 2015 | -23.08% |
| Mar 31, 2015 | 14.87% |
| Dec 31, 2014 | -24.10% |
| Sep 30, 2014 | 0.03% |
| Jun 30, 2014 | -13.96% |
| Mar 31, 2014 | 0.45% |
| Dec 31, 2013 | -9.10% |
| Sep 30, 2013 | -8.78% |
| Jun 30, 2013 | -14.28% |
| Mar 31, 2013 | -10.15% |
| Dec 31, 2012 | -13.41% |
| Sep 30, 2012 | -60.12% |
| Jun 30, 2012 | -4.19% |
| Mar 31, 2012 | 13.79% |
| Dec 31, 2011 | 4.16% |
| Sep 30, 2011 | 7.91% |
| Jun 30, 2011 | 5.69% |
| Mar 31, 2011 | 8.46% |
| Dec 31, 2010 | -0.02% |
| Sep 30, 2010 | 6.96% |
| Jun 30, 2010 | 6.61% |
| Mar 31, 2010 | 3.04% |
| Dec 31, 2009 | -2.25% |
| Sep 30, 2009 | 5.18% |
| Jun 30, 2009 | 6.37% |
| Mar 31, 2009 | 0.69% |